<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Intern Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Intern. Med</journal-id>
      <journal-id journal-id-type="doi">10.2169/internalmedicine.55.6738</journal-id>
      <journal-title-group>
        <journal-title>Internal Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0918-2918</issn>
      <issn pub-type="epub">1349-7235</issn>
      <publisher>
        <publisher-name>The Japanese Society of Internal Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27803410</article-id>
      <article-id pub-id-type="pmc">5140865</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (<italic>ALK</italic>) Rearrangement Successfully Treated by an <italic>ALK</italic> Inhibitor</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Nakajima</surname>
            <given-names>Masayuki</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Uchiyama</surname>
            <given-names>Naoki</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shigemasa</surname>
            <given-names>Rie</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matsumura</surname>
            <given-names>Takeshi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matsuoka</surname>
            <given-names>Ryota</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nomura</surname>
            <given-names>Akihiro</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Department of Respiratory Medicine, Ibaraki Seinan Medical Center Hospital, Japan</aff>
        <aff id="aff2"><label>2</label>Department of Laboratory Medicine and Pathology, Ibaraki Seinan Medical Center Hospital, Japan</aff>
        <aff id="aff3"><label>3</label>Department of Pathology, Graduate School of Comprehensive Human Science, University of Tsukuba, Japan</aff>
      </contrib-group>
      <author-notes>
        <fn>
          <p>Correspondence to Dr.&#x3000;Akihiro Nomura, <email>kokyuuki-nomura@seinan-mch.or.jp</email></p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>1</day>
        <month>11</month>
        <year>2016</year>
      </pub-date>
      <volume>55</volume>
      <issue>21</issue>
      <fpage>3151</fpage>
      <lpage>3153</lpage>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>10</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>9</day>
          <month>3</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p><!--CREATIVE COMMONS-->The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>This is the first report in which crizotinib, an anaplastic lymphoma kinase (<italic>ALK</italic>) inhibitor, reduced an atypical carcinoid tumor with <italic>ALK</italic> rearrangement. A 70-year-old man developed a tumor in the left lung and multiple metastases to the lung and brain. The pathology of transbronchial biopsied specimens demonstrated an atypical carcinoid pattern. Combined with immunohistochemical findings, we diagnosed the tumor as atypical carcinoid. <italic>ALK</italic> gene rearrangement was observed by both immunohistochemical (IHC) and fluorescence <italic>in situ</italic> hybridization. He was treated with chemotherapy as first-line therapy, however, the tumor did not respond to chemotherapy. Thereafter, he was treated with crizotinib, which successfully reduced the tumors. </p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>carcinoid tumor</kwd>
        <kwd><italic>ALK</italic> rearrangement</kwd>
        <kwd>crizotinib</kwd>
        <kwd><italic>ALK</italic> inhibitor</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Case Report</title>
      <p>A 70-year-old Japanese man with a 50-year, 10 cigarettes/day smoking history presented with hoarseness. Chest computed tomography (CT) and brain magnetic resonance imaging (MRI) showed a tumor in the left lung and multiple metastases to the lung, the bone, and brain. Among serum tumor markers, neuron-specific enolase (68.9 ng/mL) and progastrin-releasing peptide (862 pg/mL) were elevated. The pathology of transbronchial biopsied specimens demonstrated acidophilic tumor cells showing a cord-like distribution with small necrosis and one mitosis in 10 high-power fields (<xref ref-type="fig" rid="g001">Fig. 1</xref>). Combined with immunohistochemical (IHC) findings of CD56+/chromogranin A+/synaptophysin+ (<xref ref-type="fig" rid="g002">Fig. 2A</xref>) and a low Ki-67 labeling index (&lt;20%), we diagnosed the tumor as atypical carcinoid.</p>
      <fig id="g001" orientation="portrait" position="float">
        <label>Figure 1.</label>
        <caption>
          <p>Biopsied specimens stained with Hematoxylin and Eosin staining show small necrotic foci (inset) and tumor cells with fine nuclear chromatin and moderate eosinophilic cytoplasm growing in a trabecular pattern and organoid nesting arrangement. Only one mitosis was found in 10 high-power fields.</p>
        </caption>
        <graphic xlink:href="1349-7235-55-3151-g001"/>
      </fig>
      <fig id="g002" orientation="portrait" position="float">
        <label>Figure 2.</label>
        <caption>
          <p>HC for (A) synaptophysin and (B) <italic>ALK</italic>. (C) FISH analysis of the <italic>ALK</italic> locus using a break-apart probe strategy. Strongly positive staining for synaptophysin (Bb) (A) and <italic>ALK</italic> (5A4, Nichirei Biosciences, Tokyo) (B) was observed in tumor cells. (C) Approximately 74% of the tumor cells showed rearrangement at the <italic>ALK</italic> locus.
</p>
        </caption>
        <graphic xlink:href="1349-7235-55-3151-g002"/>
      </fig>
      <p>Further analyses revealed that anaplastic lymphoma kinase (<italic>ALK</italic>) gene rearrangement was observed by both IHC (<xref ref-type="fig" rid="g002">Fig. 2B</xref>) and fluorescence <italic>in situ</italic> hybridization (FISH) (<xref ref-type="fig" rid="g002">Fig. 2C</xref>). Epidermal growth factor receptor mutations were not observed. The patient was initially treated with carboplatin (AUC5, day 1) and etoposide (100 mg/m<sup>2</sup>, days 1-3), however, the tumor size remained unchanged after four cycles of chemotherapy. Thereafter, he was treated with an <italic>ALK</italic> inhibitor, crizotinib (Pfizer, Tokyo, Japan) 250 mg PO twice daily, which reduced the tumors in the lung (<xref ref-type="fig" rid="g003">Fig. 3A and B</xref>) and the brain (<xref ref-type="fig" rid="g003">Fig. 3C and D</xref>) by 42% and 53%, respectively, over 3 months.</p>
      <fig id="g003" orientation="portrait" position="float">
        <label>Figure 3.</label>
        <caption>
          <p>A chest CT scan and brain MRI before and during treatment with crizotinib (A and C: May 2015, B and D: Aug 2015). Crizotinib reduced the primary mass (arrows) from 26 mm (A) to 15 mm (B), and the multiple lung metastases (arrowheads) disappeared. Crizotinib also reduced the brain metastasis (arrows) from 13.3 mm (C) to 6.2 mm (D).</p>
        </caption>
        <graphic xlink:href="1349-7235-55-3151-g003"/>
      </fig>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>Although <italic>ALK</italic> rearrangement accounts for approximately 5% of non-small cell lung carcinomas (NSCLCs), <italic>ALK</italic> rearrangement in neuroendocrine tumors (NETs) including small cell lung carcinomas (SCLCs), large cell neuroendocrine carcinomas (LCNECs), and carcinoid tumors is quite rare (<xref rid="B1" ref-type="bibr">1</xref>). To date, only four NET cases, two SCLC cases, one LCNEC case and one atypical carcinoid tumor case have been reported to have <italic>ALK</italic> rearrangement (<xref rid="B2" ref-type="bibr">2</xref>-<xref rid="B5" ref-type="bibr">5</xref>). In addition, Nakamura and colleagues reported that no <italic>ALK</italic> rearrangement was found among 227 NETs including 52 carcinoid tumors (<xref rid="B6" ref-type="bibr">6</xref>).</p>
      <p>The biopsied tissues in the present case were optimal specimens without crushing for microscopic observation, and <italic>ALK</italic> rearrangement was confirmed using two methods (IHC and FISH). We thus contend that the lung tumor in the present case met the criteria of atypical carcinoid tumor, and that this atypical carcinoid tumor also had <italic>ALK</italic> rearrangement. However, a potential limitation of this case is that the pathology of transbronchial biopsied specimens may not reflect the character of the whole tumor.</p>
      <p>The patient's outcome demonstrated that crizotinib successfully reduced his atypical carcinoid tumor. The treatment of metastatic carcinoid tumors has not yet been established. We first treated our patient with chemotherapy according to a previous report (<xref rid="B7" ref-type="bibr">7</xref>), however, the regimen was ineffective. We then administered crizotinib, and it reduced the tumors in both the lung and brain.</p>
      <p>However, it was also reported that NETs with <italic>ALK</italic> rearrangement may be resistant to <italic>ALK</italic> inhibitors (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>). Further analyses are needed to elucidate whether crizotinib may become a key tool for the treatment of carcinoid tumors with <italic>ALK</italic> rearrangement.</p>
    </sec>
    <sec>
      <title>The authors state that they have no Conflict of Interest (COI).</title>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soda</surname><given-names>M</given-names></name>, <name><surname>Choi</surname><given-names>YL</given-names></name>, <name><surname>Enomoto</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</article-title>. <source>Nature</source>
<volume>448</volume>: <fpage>561</fpage>-<lpage>566</lpage>, <year>2007</year>.<pub-id pub-id-type="pmid">17625570</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Omachi</surname><given-names>N</given-names></name>, <name><surname>Shimizu</surname><given-names>S</given-names></name>, <name><surname>Kawaguchi</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>
<article-title>A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib</article-title>. <source>J Thorac Oncol</source>
<volume>9</volume>: <fpage>e40</fpage>-<lpage>e42</lpage>, <year>2014</year>.<pub-id pub-id-type="pmid">24828670</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fukuizumi</surname><given-names>A</given-names></name>, <name><surname>Akagi</surname><given-names>K</given-names></name>, <name><surname>Sakai</surname><given-names>H</given-names></name></person-group>
<article-title>A case of atypical carcinoid: harboring variant 3a/b EML4-ALK rearrangement</article-title>. <source>J Thorac Oncol</source>
<volume>10</volume>: <fpage>e104</fpage>-<lpage>e106</lpage>, <year>2015</year>.<pub-id pub-id-type="pmid">26398829</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Toyokawa</surname><given-names>G</given-names></name>, <name><surname>Taguchi</surname><given-names>K</given-names></name>, <name><surname>Ohba</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>
<article-title>First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component</article-title>. <source>J Thorac Oncol</source>
<volume>7</volume>: <fpage>e39</fpage>-<lpage>e41</lpage>, <year>2012</year>.<pub-id pub-id-type="pmid">23154565</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Toyokawa</surname><given-names>G</given-names></name>, <name><surname>Takenoyama</surname><given-names>M</given-names></name>, <name><surname>Taguchi</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group>
<article-title>An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene</article-title>. <source>Lung Cancer</source>
<volume>81</volume>: <fpage>487</fpage>-<lpage>490</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23787064</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>H</given-names></name>, <name><surname>Tsuta</surname><given-names>K</given-names></name>, <name><surname>Yoshida</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma</article-title>. <source>J Clin Pathol</source>
<volume>66</volume>: <fpage>705</fpage>-<lpage>707</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23618692</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martini</surname><given-names>N</given-names></name>, <name><surname>Zaman</surname><given-names>MB</given-names></name>, <name><surname>Bains</surname><given-names>MS</given-names></name>, <etal>et al</etal></person-group>
<article-title>Treatment and prognosis in bronchial carcinoids involving regional lymph nodes</article-title>. <source>J Thorac Cardiovasc Surg</source>
<volume>107</volume>: <fpage>1</fpage>-<lpage>6</lpage>, <year>1994</year>.<pub-id pub-id-type="pmid">8283871</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
